PHASE II TRIAL OF GEMCITABINE AND DOCETAXEL WITH BEVACIZUMAB IN SELECTED SARCOMA SUBTYPES.
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2016
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Filgrastim; Gemcitabine; Pegfilgrastim
- Indications Haemangiosarcoma; Leiomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 17 Dec 2015 Protocol has been amended in change in time frame of primary endpoint from 2 years to 6 months.
- 01 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 23 Jan 2014 Planned End Date changed from 1 Apr 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov record.